RT Journal Article SR Electronic T1 Use of Droplet Digital Polymerase Chain Reaction for Detecting Minimal Residual Disease: A Prospective Multi-Institutional Study JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 2273 OP 2280 DO 10.21873/invivo.11733 VO 33 IS 6 A1 HYUNKYUNG PARK A1 DONG-YEOP SHIN A1 INHO KIM A1 SANG-KYUN SOHN A1 YOUNGIL KOH A1 JE-HWAN LEE A1 KYOO-HYUNG LEE A1 DAE-YOUNG KIM A1 HYEONG-JOON KIM A1 JAE-SOOK AHN A1 JEONG-OK LEE A1 SOO-MEE BANG A1 JUNE-WON CHEONG A1 SANG-GON PARK A1 SEONYANG PARK A1 YOO JIN LEE A1 SEO-YEON AHN YR 2019 UL http://iv.iiarjournals.org/content/33/6/2273.abstract AB Background/Aim: Droplet digital polymerase chain reaction (ddPCR) is an exact method of measuring nucleic acids. The aim of this prospective study was to evaluate minimal residual disease (MRD) using ddPCR in chronic myeloid leukemia (CML) patients. Patients and Methods: Between May 2013 and November 2014, CML patients treated with nilotinib were enrolled in our study. BCR/ABL1 transcripts levels were evaluated using ddPCR at the first time of complete molecular response (CMR). We enrolled 15 patients from 7 Institutions. The treatment period and median follow-up period were 45 months and 47 months, respectively. Results: Patients with a high level of BCR/ABL1 transcript had a greater tendency to lose the CMR during the follow-up period (p=0.095). In addition, patients with a low level of BCR/ABL1 transcript showed a longer duration of CMR compared to those with a high level (p=0.032). Conclusion: We found that ddPCR is a sensitive method for detecting MRD and that MRD could affect the duration of the treatment response.